In Your Role As A Biopharmaceutical Angel Investor, What Are Some Questions You Ask And Why?

A: I ASK THREE QUESTIONS about a compound: Can it be made? Is it safe? Does it work? Obviously, there are no definite answers at an early development stage, but likelihood of a “yes” needs to be assessed. I am not asking for predicted peak sales evaluation (or anything similar) because it is a nonsensical number anyway. Most compounds that meet the above criteria will exit with at least a decent return to early-stage investors. I also ask if the “story” is simple. Complex science produces wonderful publications, but not very often does it translate to useful medicines. I also ask the founders a few questions to get a sense of their commitment to building value.

TOMASZ SABLINSKI, M.D., PH.D.
Tomasz is cofounder and CEO of Transparency Life Sciences.